N-oleoyl alanine attenuates nicotine reward and spontaneous nicotine withdrawal in mice

Kimberly N Karin; Mohammed A Mustafa; Justin L Poklis; Belle Buzzi; Joel E Schlosburg; Linda Parker; M Imad Damaj; Aron H Lichtman

doi:10.1016/j.drugalcdep.2024.111276

N-oleoyl alanine attenuates nicotine reward and spontaneous nicotine withdrawal in mice

Drug Alcohol Depend. 2024 Apr 4:259:111276. doi: 10.1016/j.drugalcdep.2024.111276. Online ahead of print.

Authors

Kimberly N Karin¹, Mohammed A Mustafa¹, Justin L Poklis¹, Belle Buzzi¹, Joel E Schlosburg¹, Linda Parker², M Imad Damaj¹, Aron H Lichtman³

Affiliations

¹ Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
² Department of Psychology, University of Guelph, Guelph, Ontario, Canada.
³ Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA; Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: alichtma@vcu.edu.

PMID: 38676968
DOI: 10.1016/j.drugalcdep.2024.111276

Abstract

Background: As nicotine dependence represents a longstanding major public health issue, new nicotine cessation pharmacotherapies are needed. Administration of N-oleoyl glycine (OlGly), an endogenous lipid signaling molecule, prevents nicotine-induced conditioned place preference (CPP) through a peroxisome proliferator-activated receptor-alpha (PPARα) dependent mechanism, and also ameliorated withdrawal signs in nicotine-dependent mice. Pharmacological evidence suggests that the methylated analog of OlGly, N-oleoyl alanine (OlAla), has an increased duration of action and may offer translational benefit. Accordingly, OlAla was assessed in nicotine CPP and dependence assays as well as its pharmacokinetics compared to OlGly.

Methods: ICR female and male mice were tested in nicotine-induced CPP with and without the PPARα antagonist GW6471. OlAla was also assessed in nicotine-dependent mice following removal of nicotine minipumps: somatic withdrawal signs, thermal hyper-nociception and altered affective behavior (i.e., light/dark box). Finally, plasma and brain were collected after administration of OlGly or OlAla and analyzed by high-performance liquid chromatography tandem mass spectrometry.

Results: OlAla prevented nicotine-induced CPP, but this effect was not blocked by GW6471. OlAla attenuated somatic and affective nicotine withdrawal signs, but not thermal hyper-nociception in nicotine-dependent mice undergoing withdrawal. OlAla and OlGly showed similar time-courses in plasma and brain.

Conclusions: The observation that both molecules showed similar pharmacokinetics argues against the notion that OlAla offers increased metabolic stability. Moreover, while these structurally similar lipids show efficacy in mouse models of reward and dependence, they reduce nicotine reward through distinct mechanisms.

Keywords: Conditioned place preference (CPP); N-oleoyl alanine; Nicotine withdrawal; Peroxisome proliferator-activated receptor alpha (PPAR-α).